Logo image of COV.CA

COVALON TECHNOLOGIES LTD (COV.CA) Stock Fundamental Analysis

Canada - TSX Venture Exchange - TSX-V:COV - CA22282D3022 - Common Stock

1.92 CAD
-0.02 (-1.03%)
Last: 12/1/2025, 7:00:00 PM
Fundamental Rating

7

Overall COV gets a fundamental rating of 7 out of 10. We evaluated COV against 23 industry peers in the Biotechnology industry. COV scores excellent points on both the profitability and health parts. This is a solid base for a good stock. COV is not valued too expensively and it also shows a decent growth rate. With these ratings, COV could be worth investigating further for quality investing!.


Dividend Valuation Growth Profitability Health

7

1. Profitability

1.1 Basic Checks

COV had positive earnings in the past year.
In the past year COV had a positive cash flow from operations.
In multiple years COV reported negative net income over the last 5 years.
The reported operating cash flow has been mixed in the past 5 years: COV reported negative operating cash flow in multiple years.
COV.CA Yearly Net Income VS EBIT VS OCF VS FCFCOV.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M 20M

1.2 Ratios

COV's Return On Assets of 6.56% is amongst the best of the industry. COV outperforms 100.00% of its industry peers.
COV has a better Return On Equity (7.78%) than 100.00% of its industry peers.
With an excellent Return On Invested Capital value of 5.16%, COV belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
Industry RankSector Rank
ROA 6.56%
ROE 7.78%
ROIC 5.16%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
COV.CA Yearly ROA, ROE, ROICCOV.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50

1.3 Margins

With an excellent Profit Margin value of 7.00%, COV belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
In the last couple of years the Profit Margin of COV has declined.
COV has a better Operating Margin (6.60%) than 100.00% of its industry peers.
COV's Operating Margin has improved in the last couple of years.
Looking at the Gross Margin, with a value of 55.68%, COV belongs to the top of the industry, outperforming 91.30% of the companies in the same industry.
In the last couple of years the Gross Margin of COV has remained more or less at the same level.
Industry RankSector Rank
OM 6.6%
PM (TTM) 7%
GM 55.68%
OM growth 3Y233.18%
OM growth 5YN/A
PM growth 3Y-58.52%
PM growth 5YN/A
GM growth 3Y7.01%
GM growth 5Y-1.09%
COV.CA Yearly Profit, Operating, Gross MarginsCOV.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 100

8

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so COV is destroying value.
COV has more shares outstanding than it did 5 years ago.
COV.CA Yearly Shares OutstandingCOV.CA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2024 5M 10M 15M 20M 25M
COV.CA Yearly Total Debt VS Total AssetsCOV.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2024 10M 20M 30M 40M

2.2 Solvency

An Altman-Z score of 6.43 indicates that COV is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 6.43, COV belongs to the top of the industry, outperforming 86.96% of the companies in the same industry.
The Debt to FCF ratio of COV is 0.29, which is an excellent value as it means it would take COV, only 0.29 years of fcf income to pay off all of its debts.
COV has a Debt to FCF ratio of 0.29. This is amongst the best in the industry. COV outperforms 100.00% of its industry peers.
COV has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.
COV has a Debt to Equity ratio of 0.02. This is in the better half of the industry: COV outperforms 73.91% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF 0.29
Altman-Z 6.43
ROIC/WACC0.67
WACC7.73%
COV.CA Yearly LT Debt VS Equity VS FCFCOV.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M 20M 30M

2.3 Liquidity

A Current Ratio of 6.57 indicates that COV has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 6.57, COV belongs to the top of the industry, outperforming 86.96% of the companies in the same industry.
A Quick Ratio of 4.91 indicates that COV has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 4.91, COV belongs to the best of the industry, outperforming 82.61% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 6.57
Quick Ratio 4.91
COV.CA Yearly Current Assets VS Current LiabilitesCOV.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2024 10M 20M 30M

5

3. Growth

3.1 Past

COV shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 350.62%, which is quite impressive.
Measured over the past years, COV shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -50.83% on average per year.
COV shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 13.00%.
The Revenue has been decreasing by -1.73% on average over the past years.
EPS 1Y (TTM)350.62%
EPS 3Y-50.83%
EPS 5YN/A
EPS Q2Q%-100%
Revenue 1Y (TTM)13%
Revenue growth 3Y16.8%
Revenue growth 5Y-1.73%
Sales Q2Q%-8.67%

3.2 Future

Based on estimates for the next years, COV will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.89% on average per year.
Based on estimates for the next years, COV will show a quite strong growth in Revenue. The Revenue will grow by 9.88% on average per year.
EPS Next Y-92.31%
EPS Next 2Y-3.92%
EPS Next 3Y9.35%
EPS Next 5Y15.89%
Revenue Next Year12.07%
Revenue Next 2Y11.1%
Revenue Next 3Y10.54%
Revenue Next 5Y9.88%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
COV.CA Yearly Revenue VS EstimatesCOV.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 10M 20M 30M 40M 50M
COV.CA Yearly EPS VS EstimatesCOV.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 2028 2029 2030 0.1 0.2 0.3

6

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 24.00, COV is valued on the expensive side.
Compared to the rest of the industry, the Price/Earnings ratio of COV indicates a rather cheap valuation: COV is cheaper than 100.00% of the companies listed in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 26.15, COV is valued at the same level.
The Price/Forward Earnings ratio is 15.53, which indicates a correct valuation of COV.
Based on the Price/Forward Earnings ratio, COV is valued cheaper than 91.30% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of COV to the average of the S&P500 Index (36.22), we can say COV is valued rather cheaply.
Industry RankSector Rank
PE 24
Fwd PE 15.53
COV.CA Price Earnings VS Forward Price EarningsCOV.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, COV is valued cheaply inside the industry as 100.00% of the companies are valued more expensively.
100.00% of the companies in the same industry are more expensive than COV, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 12.11
EV/EBITDA 11.57
COV.CA Per share dataCOV.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0.2 0.4 0.6 0.8 1

4.3 Compensation for Growth

COV has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-3.92%
EPS Next 3Y9.35%

4

5. Dividend

5.1 Amount

With a Yearly Dividend Yield of 7.73%, COV is a good candidate for dividend investing.
COV's Dividend Yield is rather good when compared to the industry average which is at 7.73. COV pays more dividend than 100.00% of the companies in the same industry.
Compared to an average S&P500 Dividend Yield of 2.32, COV pays a better dividend.
Industry RankSector Rank
Dividend Yield 7.73%

5.2 History

COV does not have a reliable dividend history as it only pays dividend since a couple or years.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
COV.CA Yearly Dividends per shareCOV.CA Yearly Dividends per shareYearly Dividends per share 2025 0.05 0.1

5.3 Sustainability

DPN/A
EPS Next 2Y-3.92%
EPS Next 3Y9.35%
COV.CA Yearly Income VS Free CF VS DividendCOV.CA Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M 20M

COVALON TECHNOLOGIES LTD

TSX-V:COV (12/1/2025, 7:00:00 PM)

1.92

-0.02 (-1.03%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-21 2025-08-21/bmo
Earnings (Next)01-05 2026-01-05
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners5.11%
Ins Owner ChangeN/A
Market Cap53.03M
Revenue(TTM)32.99M
Net Income(TTM)2.31M
Analysts84.44
Price Target3.83 (99.48%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 7.73%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-Date11-04 2025-11-04 (0.15)
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2.91%
Min EPS beat(2)-100%
Max EPS beat(2)94.17%
EPS beat(4)2
Avg EPS beat(4)40.61%
Min EPS beat(4)-100%
Max EPS beat(4)229.45%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-8.47%
Min Revenue beat(2)-12.98%
Max Revenue beat(2)-3.96%
Revenue beat(4)1
Avg Revenue beat(4)0.71%
Min Revenue beat(4)-12.98%
Max Revenue beat(4)32.12%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-80%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)4.86%
Revenue NY rev (1m)4.02%
Revenue NY rev (3m)1.18%
Valuation
Industry RankSector Rank
PE 24
Fwd PE 15.53
P/S 1.61
P/FCF 12.11
P/OCF 10.45
P/B 1.79
P/tB 1.87
EV/EBITDA 11.57
EPS(TTM)0.08
EY4.17%
EPS(NY)0.12
Fwd EY6.44%
FCF(TTM)0.16
FCFY8.26%
OCF(TTM)0.18
OCFY9.57%
SpS1.19
BVpS1.07
TBVpS1.03
PEG (NY)N/A
PEG (5Y)N/A
Graham Number1.39
Profitability
Industry RankSector Rank
ROA 6.56%
ROE 7.78%
ROCE 7.16%
ROIC 5.16%
ROICexc 12.73%
ROICexgc 14.27%
OM 6.6%
PM (TTM) 7%
GM 55.68%
FCFM 13.27%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y199.36%
ROICexgc growth 5YN/A
ROICexc growth 3Y198.52%
ROICexc growth 5YN/A
OM growth 3Y233.18%
OM growth 5YN/A
PM growth 3Y-58.52%
PM growth 5YN/A
GM growth 3Y7.01%
GM growth 5Y-1.09%
F-Score5
Asset Turnover0.94
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF 0.29
Debt/EBITDA 0.23
Cap/Depr 73.17%
Cap/Sales 2.11%
Interest Coverage 250
Cash Conversion 162.18%
Profit Quality 189.61%
Current Ratio 6.57
Quick Ratio 4.91
Altman-Z 6.43
F-Score5
WACC7.73%
ROIC/WACC0.67
Cap/Depr(3y)94.27%
Cap/Depr(5y)67.08%
Cap/Sales(3y)4.08%
Cap/Sales(5y)2.94%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)350.62%
EPS 3Y-50.83%
EPS 5YN/A
EPS Q2Q%-100%
EPS Next Y-92.31%
EPS Next 2Y-3.92%
EPS Next 3Y9.35%
EPS Next 5Y15.89%
Revenue 1Y (TTM)13%
Revenue growth 3Y16.8%
Revenue growth 5Y-1.73%
Sales Q2Q%-8.67%
Revenue Next Year12.07%
Revenue Next 2Y11.1%
Revenue Next 3Y10.54%
Revenue Next 5Y9.88%
EBIT growth 1Y258.74%
EBIT growth 3Y289.15%
EBIT growth 5YN/A
EBIT Next Year-50.79%
EBIT Next 3Y21.1%
EBIT Next 5Y21.3%
FCF growth 1Y225.56%
FCF growth 3Y-51.66%
FCF growth 5YN/A
OCF growth 1Y353.8%
OCF growth 3Y-49.67%
OCF growth 5YN/A

COVALON TECHNOLOGIES LTD / COV.CA FAQ

Can you provide the ChartMill fundamental rating for COVALON TECHNOLOGIES LTD?

ChartMill assigns a fundamental rating of 7 / 10 to COV.CA.


What is the valuation status of COVALON TECHNOLOGIES LTD (COV.CA) stock?

ChartMill assigns a valuation rating of 6 / 10 to COVALON TECHNOLOGIES LTD (COV.CA). This can be considered as Fairly Valued.


Can you provide the profitability details for COVALON TECHNOLOGIES LTD?

COVALON TECHNOLOGIES LTD (COV.CA) has a profitability rating of 7 / 10.


What is the earnings growth outlook for COVALON TECHNOLOGIES LTD?

The Earnings per Share (EPS) of COVALON TECHNOLOGIES LTD (COV.CA) is expected to decline by -92.31% in the next year.